Last Updated : February 10, 2025
Details
FilesGeneric Name:
panitumumab
Project Status:
Complete
Therapeutic Area:
Left-sided metastatic colorectal cancer (mCRC)
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0333-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
In combination with chemotherapy, for the first-line treatment of mCRC patients with left-sided primary tumours that express wild-type RAS.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
| Call for patient/clinician input open | 13-Jul-23 |
|---|---|
| Call for patient/clinician input closed | 01-Sep-23 |
| Clarification: - Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network (CCRAN) | |
| Call for industry input open | 13-Jul-23 |
| Call for industry input closed | 01-Sep-23 |
| Submission received | 19-May-23 |
| Review initiated | 18-Jul-23 |
| Expert committee meeting (initial) | 01-Feb-24 |
| Draft recommendation posted for stakeholder feedback | 28-Feb-24 |
| End of feedback period | 13-Mar-24 |
| Final recommendation posted | 18-Apr-24 |
| CADTH review report(s) posted | 29-Jul-24 |
Files
Last Updated : February 10, 2025